Shukui Qin

Summary

Affiliation: The First Affiliated Hospital
Country: China

Publications

  1. ncbi Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  2. ncbi Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells
    Qiong Wu
    Department of Medical Oncology, Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
    J Hematol Oncol 3:43. 2010
  3. ncbi Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
    Winnie Yeo
    Prince of Wales Hospital, Shatin, Hong Kong
    BMC Cancer 10:620. 2010
  4. ncbi Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients
    Haiqing Hua
    Bayi Post doctoral Workstation, Nanjing General Hospital of Nanjing Military Command Post Doctoral Research Station, Nanjing, China
    Asian Pac J Cancer Prev 12:61-5. 2011

Collaborators

  • Haiqing Hua
  • Bernard A Fox
  • Winnie Yeo
  • Qiong Wu
  • Elizabeth M Jaffee
  • Laurence Zitvogel
  • Tara Withington
  • Jens Peter Marschner
  • Kristen Hege
  • Jirina Bartunkova
  • Ignacio Melero
  • Lloyd J Old
  • Hyam I Levitsky
  • Michele Maio
  • Jonathan L Bramson
  • Michael I Nishimura
  • Cornelius Melief
  • Mohamed L Salem
  • Cristina Maccalli
  • Giuseppe Masucci
  • Xuetao Cao
  • Michael Papamichail
  • Giorgio Parmiani
  • Ena Wang
  • Dolores J Schendel
  • Jill O'Donnell-Tormey
  • Ronald B Herberman
  • Alfred E Chang
  • Thomas F Gajewski
  • Christian Ottensmeier
  • Robert O Dillman
  • Axel Hoos
  • Francesco M Marincola
  • Heinz Zwierzina
  • Paul von Hoegen
  • Brad Nelson
  • Kohzoh Imai
  • Hideaki Tahara
  • Jinheng Li
  • Mary L Disis
  • Dainius Characiejus
  • Michele Guida
  • Jared A Gollob
  • Marij Jp Welters
  • Lindy G Durrant
  • George Coukos
  • Lisa H Butterfield
  • Robert Rees
  • Paolo Antonio Ascierto
  • A Raja Choudhury
  • Glenn Dranoff
  • Pedro J Romero
  • Per thor Straten
  • Ernest Borden
  • Gerd Ritter
  • Beatrix Kotlan
  • Cristina C Bonorino
  • William E Carson
  • James P Allison
  • Ulrich Keilholtz
  • Rik J Scheper
  • Michael J Mastrangelo
  • Licia Rivoltini
  • Weihua Xiao
  • Harry Dolstra
  • Carl H June
  • Hauke Winter
  • Sylvia Janetzki
  • Jianzhong Rui
  • Enrico Proietti
  • Andrea Nicolini
  • Tanja de Gruijl
  • Cecile Gouttefangeas
  • Michael T Lotze
  • William J Murphy
  • Padmanee Sharma
  • Koji Kawakami
  • Yutaka Kawakami
  • Ruggero Ridolfi
  • Rejean Lapointe
  • Kunle Odunsi
  • Cedrik M Britten
  • Hiroshi Shiku
  • Sjoerd H van der Burg
  • Graham Pawelec
  • Pamela S Ohashi
  • Neil Berinstein
  • Fabio Grizzi
  • Howard L Kaufman
  • Jedd D Wolchok

Detail Information

Publications4

  1. ncbi Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  2. ncbi Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells
    Qiong Wu
    Department of Medical Oncology, Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
    J Hematol Oncol 3:43. 2010
    ..In the present study, the effect of lobaplatin was assessed in five HCC cell lines and the underlying molecular mechanisms in terms of cell cycle kinetics were explored...
  3. ncbi Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma
    Winnie Yeo
    Prince of Wales Hospital, Shatin, Hong Kong
    BMC Cancer 10:620. 2010
    ..Finally, Asian nations must be urged to participate in clinical trials, many of which are ongoing, to advance new treatment options in this challenging disease...
  4. ncbi Pharmacokinetics of arsenic trioxide (As₂O₃) in Chinese primary hepatocarcinoma patients
    Haiqing Hua
    Bayi Post doctoral Workstation, Nanjing General Hospital of Nanjing Military Command Post Doctoral Research Station, Nanjing, China
    Asian Pac J Cancer Prev 12:61-5. 2011
    ..Pharmacokinetics after As₂O₃ injection into patients with a primary hepatocarcinoma (PHC) were therefore investigated...